Pharmaceutical compositions comprising meloxicam
AssigneeAxsome Therapeutics, Inc.
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Loading patent…
AssigneeAxsome Therapeutics, Inc.
InventorHerriot Tabuteau
Estimating the term…
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A method of reducing the Tmax of rizatriptan, comprising orally administering a monolayer tablet to a human patient experiencing a migraine, wherein the monolayer tablet comprises 20 mg of meloxicam, 10 mg of rizatriptan, sodium bicarbonate, and a sulfobutylether-β-cyclodextrin (SBEβCD), wherein administering the monolayer tablet to the human patient results in the human patient having a Tmax of rizatriptan that is about 0.75 hours.
Dependencies are inferred from the claim text.